Pfizer,the world's largest pharmaceutical company,is collaborating on the study of liver cancer tumors from Korean patients with Samsung Medical Center in Seoul,South Korea.This joint research will generate genetic profiles and aims to direct therapies and enhance outcomes for liver cancer patients.Professor Park Cheol-Guen in Seoul and Dr.Neil Gibson,Pfizer's Vice President of Oncology Research,are among the participating scientists.
Liver cancer is especially common in Asia.Pfizer took note of South Korea's world class research environment and chose it as the hub for addressing Asia's pressing need for a liver cancer drug.SMC has been building a large liver cancer specimen collection and developing collaboration with research partners,expanding the knowledge base for liver cancer diagnosis and treatment.The institute has been designated a member of the Group of Leading Research Hospitals by the South Korean government.Choi Han-Yung,President of SMC,said the goal is to send a new message of hope for patients with liver cancer across the world-especially in Asia.Dr.Gibson explained that the partnership will combine Pfizer's competence in drug development with SMC's extensive genome information and technology in the liver cancer area.
Liver cancer is uncommon in the U.S.,but the rates of diagnosis are increasing.Chronic infection with hepatitis viruses is one known cause of the disease.As well,diabetes patients are at greater risk of developing liver cancer.
Pfizer(PFE)
No comments:
Post a Comment